Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Participants With Advanced Hepatocellular Carcinoma

Exclusion Criteria

• •1. Uncontrolled significant active infections, except hepatitis B virus (HBV) or hepatitis C virus (HCV).
• •2. Known human immunodeficiency virus infection.
• •3. Presence of gastric or esophageal varices requiring active treatment.
• •4. Previous treatment with a selective FGF19-FGFR4 targeted therapy.
• •5. Females of childbearing potential, or males who have not had a successful vasectomy, who are unable or unwilling to follow adequate contraceptive measures.
• •6. Hereditary problems of galactose intolerance, the Lapp lactase deficiency, or glucose-galactose malabsorption.